May 08, 2025

FDA Warns Physicians of Tianeptine Dangers

The FDA warns physicians about unapproved tianeptine products that are linked to severe adverse events, including dependence, toxicity, and death.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

May 01, 2025

FDA Approves Intranasal DHE for Acute Migraine Relief

The FDA has approved Atzumi for the acute treatment of migraine with or without aura in adults.

Conexiant

April 30, 2025

FDA Approves FcRn Blocker for Broad gMG Use

The first FcRn blocker for both adult and pediatric generalized myasthenia gravis has been approved by the FDA, based on data showing sustained symptom improvement and IgG reduction in clinical trials.

Conexiant

April 29, 2025

New Oral Option Approved for GCA

The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.

Conexiant

April 21, 2025

New Prescription App Reduces Migraine Days

The FDA has authorized CT-132, the first prescription digital therapeutic for episodic migraine prevention, based on clinical trial data showing reduced monthly migraine days.

Conexiant

April 18, 2025

Intranasal Diazepam Gains Expanded Approval for Pediatric Patients

“Approval of an immediate-use intranasal diazepam treatment that can be given at any time—even while a child is actively seizing—in this young age group is an important advance for the epilepsy community.”

Conexiant

April 15, 2025

1 in 31: Autism Rate Hits New Mark

“The true or actual rate of autism [in the United States] is more likely to be closer to what this report has identified in California or Pennsylvania."

Reuters

July 26, 2024

16 U.S. States Reach $86M Settlement with Drug Manufacturer

Indivior, a Virginia-based drug manufacturer, has reached an $86 million settlement with 16 U.S. states over its alleged role in the opioid addiction crisis, involving buprenorphine-based products. The settlement funds will be used for opioid addiction treatment, recovery, and prevention.

Reuters